Crescita Therapeutics Announces the Results of its Annual General and Special Meeting of Shareholders

LAVAL, Quebec--(BUSINESS WIRE)-- Crescita Therapeutics Inc. (TSX: CTX and OTC US: CRRTF) (“Crescita” or the “Company”), a growth-oriented, innovation-driven Canadian commercial dermatology company, today announced the voting results from its Annual General and Special Meeting of Shareholders held at its corporate headquarters in Laval, Quebec on June 5, 2024. The detailed results of the votes received by proxy are as follows:

Election of Directors

Director Nominees	NUMBER OF SHARES		PERCENTAGE OF VOTES CAST
	FOR	WITHHELD	FOR	WITHHELD
Daniel N. Chicoine	6,490,732	109,026	98.3%	1.7%
Anthony E. Dobranowski	6,508,888	90,870	98.6%	1.4%
John C. London	6,533,190	66,568	99.0%	1.0%
Deborah Shannon-Trudeau	6,541,297	58,461	99.1%	0.9%
Serge Verreault	6,590,211	9,547	99.9%	0.1%

Reappointment of External Auditors

Outcome	NUMBER OF SHARES		PERCENTAGE OF VOTES CAST
	FOR	WITHHELD	FOR	WITHHELD
Ernst & Young LLP reappointed	7,212,551	148,556	98.0%	2.0%

Approval of the Continuation of Crescita’s Share Incentive Plan

Outcome	NUMBER OF SHARES		PERCENTAGE OF VOTES CAST
	FOR	AGAINST	FOR	AGAINST
Share Incentive Plan approved	6,526,477	73,281	98.9%	1.1%

About Crescita Therapeutics Inc.

Crescita (TSX: CTX and OTC US: CRRTF) is a growth-oriented, innovation-driven Canadian commercial dermatology company with in-house R&D and manufacturing capabilities. The Company offers a portfolio of high-quality, science-based non-prescription skincare products and a commercial stage prescription product. We also own multiple proprietary transdermal delivery platforms that support the development of patented formulations to facilitate the delivery of active ingredients into or through the skin. For more information visit, www.crescitatherapeutics.com.

Source: Crescita Therapeutics

View source version on businesswire.com: https://www.businesswire.com/news/home/20240606355142/en/

Linda Kisa, CPA, CA

Vice-President, Reporting and Corporate Affairs

Email: lkisa@crescitatx.com

Source: Crescita Therapeutics